Table 1.
Demographic data in accordance with opioid receptor polymorphism
| AA (n = 82) | AG (n=97) | GG (n=21) | p value | |
|---|---|---|---|---|
| Age (year) | 48.8 ± 9.3 | 48.6±9.2 | 53.2±10.6 | 0.112 |
| Height (cm) | 157.5±6.9 | 157.6±5.8 | 157.6±5.0 | 0.977 |
| Weight [kg] | 55.4 [51.8-62.5] | 57.5 [51.7-62.4] | 56.9 [53.9-60.7] | 0.840 |
| Final pathologic results | 0.729 | |||
| DCIS | 14 (17.1) | 20 (20.6) | 5 (23.8) | |
| IBC | 68 (82.9) | 77 (79.4) | 16 (76.2) | |
| Cancer Stage | 0.729 | |||
| Stage 0 | 0 (0.0) | 1 (1.0) | 0 (0.0) | |
| Stage I | 55 (67.1) | 56 (57.7) | 15 (71.4) | |
| Stage II | 14 (17.1) | 23 (23.7) | 4 (19.0) | |
| Stage III, IV | 13 (15.9) | 17 (17.5) | 2 (9.5) | |
| Anaesthesia time (min) | 124.4±36.4 | 122.8±46.9 | 132.7±40.6 | 0.620 |
| Operation time (min) | 91.4±33.9 | 90.4±45.6 | 96.9±43.0 | 0.804 |
| Sevoflurane [vol%] Minimum |
0.7 [0.0-1.0] | 0.8 [0.0-1.0] | 0.0 [0.0-1.0] | 0.273 |
| Maximum | 1.2 [0.0-1.5] | 1.3 [0.0-1.7] | 0.0 [0.0-1.6] | 0.206 |
| Propofol [mg] | 141.9 [111.3-546.3] | 128.0 [109.4-450.5] | 277.0 [116.1-635] | 0.153 |
| Remifentanil (μg) | 2556.7.0±815.6 | 2581.8±1083.3 | 2623.1±1007.3 | 0.959 |
| Postoperative treatment | ||||
| CTx. | 48 (58.5) | 59 (60.8) | 11 (52.4) | 0.771 |
| RTx. | 77 (93.9) | 89 (91.8) | 20 (95.2) | 0.780 |
| HTx. | 72 (87.8) | 82 (84.5) | 20 (95.2) | 0.401 |
| Incidence or recurrence | 5 (6.1) | 8 (8.2) | 1 (4.8) | 0.780 |
Values are expressed as mean ± SD, median [range] or number of patients (%).
DCIS: ductal carcinoma in situ; IBC: invasive breast cancer; CTx.: chemotherapy; RTx.: radiation therapy; HTx.: hormonal therapy.